- Home
- NUS vs PGEN Comparison
NUS vs PGEN Comparison
Compare NUS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- PGEN
- Stock Information
- Founded
- NUS 1984
- PGEN 1998
- Country
- NUS United States
- PGEN United States
- Employees
- NUS N/A
- PGEN N/A
- Industry
- NUS Other Pharmaceuticals
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- PGEN Health Care
- Exchange
- NUS Nasdaq
- PGEN Nasdaq
- Market Cap
- NUS 572.2M
- PGEN 493.0M
- IPO Year
- NUS 1996
- PGEN N/A
- Fundamental
- Price
- NUS $12.15
- PGEN $4.51
- Analyst Decision
- NUS Hold
- PGEN Buy
- Analyst Count
- NUS 2
- PGEN 5
- Target Price
- NUS $6.88
- PGEN $7.50
- AVG Volume (30 Days)
- NUS 676.6K
- PGEN 17.3M
- Earning Date
- NUS 08-07-2025
- PGEN 08-12-2025
- Dividend Yield
- NUS 1.97%
- PGEN N/A
- EPS Growth
- NUS N/A
- PGEN N/A
- EPS
- NUS 2.03
- PGEN N/A
- Revenue
- NUS $1,626,325,000.00
- PGEN $4,340,000.00
- Revenue This Year
- NUS N/A
- PGEN $253.63
- Revenue Next Year
- NUS $0.98
- PGEN $699.64
- P/E Ratio
- NUS $6.00
- PGEN N/A
- Revenue Growth
- NUS N/A
- PGEN N/A
- 52 Week Low
- NUS $5.32
- PGEN $0.65
- 52 Week High
- NUS $12.41
- PGEN $4.83
- Technical
- Relative Strength Index (RSI)
- NUS 66.78
- PGEN 82.65
- Support Level
- NUS $11.83
- PGEN $2.94
- Resistance Level
- NUS $12.41
- PGEN $4.83
- Average True Range (ATR)
- NUS 0.43
- PGEN 0.40
- MACD
- NUS 0.02
- PGEN 0.19
- Stochastic Oscillator
- NUS 70.64
- PGEN 89.71
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.